my.chemie.de
With an accout for my.chemie.de you can always see everything at a glance – and you can configure your own website and individual newsletter.
Johann Wolfgang Goethe-Universität Frankfurt (Main), Pharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie
Heinfried H. Radeke studied medicine at the Hannover Medical School (MHH) and received his medical license in 1985. His Ph.D. thesis was recognized as the best research dissertation of 1986. After two years as an assistant physician at the Göttingen University Hospital, he began his career at MHH in 1987 with his research focus: the mechanisms of chronic inflammation in the field of molecular pharmacology. He completed his habilitation in this field in 1993 before further specializing as a consultant for general pharmacology and toxicology, consultant immunologist (DGfI), and consultant for clinical pharmacology (Frankfurt, 2004).
Following a four-month research project at BASF Bioresearch in Cambridge (Boston) in 1992, Heinfried Radeke spent the period 1994–1997 completing further DFG-sponsored research in the USA. This involved one year at UC San Francisco (interleukin-1 alpha and carcinogenesis), followed by two years at Case Western Reserve University in Cleveland (nephritis, differentiation of T cells). Since 2001, Prof. Radeke has been aiding the realignment of pharmazentrum frankfurt (Prof. Josef M. Pfeilschifter, dean of medical faculty and director of the Institute of General Pharmacology and Toxicology) towards immunopharmacology, from 2001 to 2008 as the Dr. Hans Schleussner Foundation Lecturer for Immunopharmacology. He plays a decisive role in the training of medical and dental students, with past positions including that of deputy director of the DFG’s largest research training group, GRK1172 Biologicals, in which over 100 doctorates were awarded from 2005 – 2014.
There are currently several very good reasons to take a closer look at biopharmaceuticals. After the introduction of „modern biologicals“ at the beginning of the 1990s, including (…)
How do killer T cells know where danger is coming from?
How do killer T cells recognise cells in the body that have been infected by viruses? Matter foreign to the body is presented on the surface of these cells as antigens that act as a kind of road sign. A network of accessory proteins – the chaperones – ensure that this sign retains its stabi ... more
Laboratory study: effect of antibodies against omicron variants BA.1 and BA.2 wears off quickly
The omicron variants BA.1 and BA.2 of the SARS-CoV-2 virus, which are dominant from about December to April, can undermine the protection against infection offered by vaccinations or survived infections after only three months. This is shown by a study from Frankfurt under the leadership of ... more
How bacteria adhere to cells: Basis for the development of a new class of antibiotics
The adhesion of bacteria to host cells is always the first and one of the decisivesteps in the development of infectious diseases. The purpose of this adhesion by infectious pathogens is first to colonize the host organism (i.e., the human body), and then to trigger an infection, which in t ... more
From feast to famine and back – no problem for bacteria
Bacteria are true survivors. In the course of evolution, they have developed numerous strategies to adapt to rapidly changing, uncertain environmental conditions. Their metabolism is much more sophisticated than that of human beings. Within minutes they can regulate their gene expression an ... more
Why biosimilars and not biogenerics?
Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group, even in expert circles. This has all changed now, however, with the recent licensing of the first bios ... more
What would medicine be without drugs? But are these drugs being used optimally today? Not at all, as we now know thanks to the findings of molecular medicine. Because for the use of these drugs, it is important to observe two aspects: the disease and the patient. Only slowly is it becom ... more
Claudia Büchel, born in 1962, studied biology at the University of Mainz, where she also received her doctorate and, in 2001, the qualification to teach plant physiology. After a postdoctoral research period at the Biological Research Centre, Szeged, she worked for four years as a research ... more
Jörg Soppa, born in 1958, studied biochemistry in Tübingen and then went on to do his doctorate at the Max Planck Institute of Biochemistry in Martinsried near Munich. In 1990 he established his own research group there and held courses at the Institute of Genetics and Microbiology of Munic ... more
Theodor Dingermann, born 1948, studied pharmacy in Erlangen and received his doctor title in 1980 to become Dr. rer. nat. In 1990 he was offered the C4 professorship at the Institute for Pharmaceutical Biology, University of Frankfurt. From 2000 to 2004 he was President of the German Phar ... more
The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.
> more about q&more
q&more is supported by:
© 1997-2022 LUMITOS AG, All rights reserved
Authors
